Desmopressin accelerates reversal of in vitro platelet dysfunction after discontinuation of eptifibatide infusion as compared with placebo. On both study days, 10 healthy volunteers received l-aspirin (250 mg intravenous bolus) and a standard eptifibatide infusion for 2 hours. After the stop of eptifibatide infusion, DDAVP or placebo were infused. Eptifibatide prolonged both CEPI-CT and CADP-CT in lepirudinised blood. Data are presented as mean ± SEM. ^*P < .05, ^**P < .01 between groups; ^#P < .05, ^##P < .01 compared with the values after eptifibatide infusion. DDAVP significantly accelerated normalization of both CEPI-CT and CADP-CT after stop of eptifibatide infusion with a maximum effect at 1.5 to 2 hours whereas the initial CADP-CT values (0-1 hour) were not affected. In contrast, CEPI-CT remained above normal in the placebo group for more than 4 hours, possibly reflecting an aspirin-like defect.